To simulate a therapeutic setting, hamsters were infected with a Wuhan D614G (S) strain of SARS-CoV-2 (hCoV-19/France/GE1973/2020, 104 TCID50/ml, 50 μl/nostril), and received daily intranasal administrations (50 μl/nostril) of either 2.5 mg/ml wild-type ACE2-Fc, 2.5 mg/ml mutACE2-Fc, or vehicle (phosphate-buffered saline, PBS), starting 24 h after infection. This evidence concerns the gene ACE2 and infection.